12-week Trial of IMO-2125 plus Ribavirin in Patients Infected with Hepatitis C Virus who have never before received any treatment for this infection

Update Il y a 4 ans
Reference: EUCTR2011-000091-33

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the safety and tolerability of different dosages of a 12-week course of IMO-2125 plus ribavirin compared to peg-rIFN plus ribavirin administered to treatment-naïve patients with chronic HCV infection


Inclusion criteria

  • Treatment-Naive Patients Infected with Hepatitis C Virus Genotype 1

Links